OptiNose AS, which focuses on treating ear, nose and throat (ENT) and allergy diseases, announced that the Pennsylvania-based pharmaceutical company’s Phase III ReOpen1 clinical trial met both co-primary endpoints.
https://www.pharmalive.com/wp-content/uploads/2022/02/OptiNose-Phase-III-Data-Signal-Hope-for-Meaningful-Sinusitis-Treatment-BioSpace-3-7-22.jpeg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2022-03-07 12:21:362022-03-07 23:07:21OptiNose Phase III Data Signal Hope for Meaningful Sinusitis Treatment